University of Oxford
This sponsor has funded 4 studies across 3 countries.
| EU PAS ID | Status | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|
| 10029 | Finalised | Risks and benefits of bisphosphonate use in patients with chronic kidney disease: a population-based cohort study | No | No |
| 17435 | Ongoing | Risk-benefit and costs of unicompartmental (compared to total) knee replacement for patients with multiple co-morbidities: a non-randomised study, and... | No | No |
| 21907 | Finalised | Excess risk and predictors of fracture/s following bariatric surgery for obese patients in the NHS: a real-world self-controlled case series and... | Yes | No |
| 104349 | Planned | Utilization of antidementia treatments: a large multinational-network population-based study. | No | No |
PAS by Risk Management Plan (RMP) requirement
University of Oxford
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
University of Oxford
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
University of Oxford
3 Study countries specified are the following:
- Denmark
- Netherlands
- United Kingdom